Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 CHRS | Healthcare | $0.52 | 3.73M | $90.02M | -0.57 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CHRS | Coherus Biosciences | 0.52 | -0.70 | -57.30% |
| Name | Price | % Change | |
|---|---|---|---|
| CHRS | $0.52 | -57.30% |
Oncolytics (ONCY) announced that it has entered into a clinical supply agreement with Coherus Oncology (CHRS) to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1
Coherus Biosciences (($CHRS)) has held its Q3 earnings call. Read on for the main highlights of the call. Coherus Biosciences’ earnings call carried a mostly positive tone as management highlighted
Reports Q3 revenue $14.27M, consensus $15.93M. “The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer
Guggenheim lowered the firm’s price target on Coherus Oncology (CHRS) to $8 from $10 and keeps a Buy rating on the shares after updating the firm’s model for Q3 results
Coherus Biosciences (CHRS) is scheduled to report 3rd quarter earnings on 11/09/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Coherus Biosciences to post earnings of -$0.22
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Coherus Biosciences, with a price target of $4.00. Jason McCarthy has given his Buy rating
H.C. Wainwright assumed coverage of Coherus Oncology (CHRS) with a Buy rating and $7 price target The company’s Loqtorzi remains the only FDA-approved and available treatment for recurrent or metastatic
Coherus Biosciences ( ($CHRS) ) just unveiled an update. On October 28, 2026, Coherus Oncology reported interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in
Coherus Oncology (CHRS) announced interim clinical data from the TREGCHECK development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy. Tagmokitug-based treatment demonstrated
Coherus Oncology (CHRS) has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business. The Company has retained Oppenheimer & Co. to serve
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| CHRS | Mar 15, 2027TBA | $90.02M | $-0.22 | $16.28M | 0.00 | -0.57 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
